Travere Therapeutics (TVTX)
(Delayed Data from NSDQ)
$9.00 USD
-0.24 (-2.60%)
Updated Aug 2, 2024 04:00 PM ET
After-Market: $9.00 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth C Momentum F VGM
Brokerage Reports
0 items in cart
Travere Therapeutics, Inc. [TVTX]
Reports for Purchase
Showing records 41 - 60 ( 131 total )
Company: Travere Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Biotechnology- ERA Highlights: ORIGIN Week 36 Data, Additional TVTX PROTECT Data
Provider: Wedbush Securities Inc.
Analyst: CHICO L
Company: Travere Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Travere Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Travere Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
The IgAN Era Continues at ERA - A Look At Anticipated Presentations
Provider: Wedbush Securities Inc.
Analyst: CHICO L
Company: Travere Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Travere Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Cohort 6 COMPOSE Data Asserts the Disease Modifying Potential of Pegtibatinase in HCU; Raise PT to $35
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Travere Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Keeping Their COMPOSEure: Phase 1/2 Results Suggests They Have A Dose
Provider: Wedbush Securities Inc.
Analyst: CHICO L
Company: Travere Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Early Days For Filspari In Inaugural Print [1Q23 Highlights]
Provider: Wedbush Securities Inc.
Analyst: CHICO L
Company: Travere Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Travere Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Early Days for Filspari In Inaugural Print [1Q23 Highlights]
Provider: Wedbush Securities Inc.
Analyst: CHICO L
Company: Travere Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Phase 3 DUPLEX FSGS Study Misses Primary eGFR Endpoint
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Travere Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Travere Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
The Slippery Slope - DUPLEX Study Fails to Meet Efficacy Endpoints
Provider: Wedbush Securities Inc.
Analyst: CHICO L
Company: Travere Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
New in Nephrology: Highlights From The WCN 2023 Meeting
Provider: Wedbush Securities Inc.
Analyst: CHICO L
Company: Travere Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
HCU Prevalence May Be Underestimated; Model Predicts Pegtibatinase''s Efficacy
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Travere Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
As The Dust Settles -- Sifting Through The Biotech Carnage, We See Opportunity
Provider: Wedbush Securities Inc.
Analyst: CHICO L
Company: Travere Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Travere Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Travere Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Travere Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
4Q Recap: First Few Days of FILSPARI Launch Encouraging; Focus Shifts to eGFR Slope Data in FSGS in 2Q; Affirm Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E